A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

开始日期2024-03-22

申办/合作机构

The Burke Medical Research Institute

[+1]

CTRI/2022/07/044161

/ Recruiting临床2期

Effect of benfotiamine as an adjuvant drug on oxidative stress in patients with type 2 diabetes mellitus Ã¢â?¬â?? a randomized double-blind placebo-controlled clinical trial

开始日期2022-07-25

申办/合作机构-

CTR20191852

/ CompletedN/A

苯磷硫胺片在老年受试者中单次给药的药代动力学研究

评价老年受试者单次服用苯磷硫胺片后的药代动力学特征。

开始日期2020-06-20

申办/合作机构

上海日馨医药科技股份有限公司

100 项与苯磷硫胺素相关的临床结果

登录后查看更多信息

100 项与苯磷硫胺素相关的转化医学

登录后查看更多信息

100 项与苯磷硫胺素相关的专利（医药）

登录后查看更多信息

427

项与苯磷硫胺素相关的文献（医药）

2024-11-15·ORGANIC PROCESS RESEARCH & DEVELOPMENT

Insights into Large-Scale Synthesis of Benfotiamine

作者: Hanganu, Anamaria ; Florea, Mihaela ; Maximov, Oana-Cristina ; Sandu, Nicoleta ; Popescu, Codruta C. ; Gârbea, Cristian ; Mirea, Anca G. ; Funeriu, Daniel P. ; Matache, Mihaela ; Maximov, Maxim

There has been increased interest in the synthesis of benfotiamine during the past few years, most likely as a direct consequence of growing market demand.It has much higher bioavailability than thiamine (vitamin B1) and therefore is more suitable for therapeutic purposes, especially in oral form.We report herein our research in an academic-private RandD project in which we investigate all aspects of the process on small and large scales.The procedure involves two labor-intensive steps, starting from thiami3ne chloride hydrochloride with the key intermediate thiamine monophosphate phosphate (TMP-the phosphate ester of thiamine monophosphate).We obtained the crystalline form of benfotiamine directly from the synthesis in the crystalline form required on the market, as proven by XRD powder spectroscopy, IR, and RAMAN.

2024-11-01·PHARMACEUTICAL CHEMISTRY JOURNAL

Antiglycation Efficacy: Unknown Pleiotropicity of Known Drugs

作者: Lebedev, P. A. ; Maslennikova, N. O. ; Sharova, O. V. ; Savirova, T. Yu. ; Zaitseva, E. N.

Aging and age-related diseases, which include the most relevant chronic non-infectious diseases (arterial hypertension, coronary heart disease, type 2 diabetes mellitus), are attributed to the accumulation of advanced glycation end-products (AGEs) in various organs and tissues.Glycation (non-enzymic glycosylation) is the name given to the in vivo reaction of reducing carbohydrates and free amino groups of proteins, lipids, and nucleic acids.It has many neg. biol. effects mediated by disruption of the conformation of structural proteins, enzymes, and nucleic acids at the intracellular level and in the extracellular matrix.The consequences of AGE accumulation are difficult to reverse because of the long half-life and slow elimination of AGEs, which makes the development of technologies aimed at blocking the reactions leading to their formation an urgent and important goal.Currently, pharmacol. is faced with the task of searching for mols. with promising antiglycating properties.Identification of drugs that prevent glycation among well-known drugs in clin. practice is a necessary step in solving this problem.The antiglycation properties of such drugs (metformin, ramipril, telmisartan, etc.) are discussed in this review as a little-known component of their pleiotropy.The drugs are classified according to the mechanism of their antiglycation effect.

2024-10-01·JOURNAL OF MOLECULAR HISTOLOGY

The protective effect of benfotiamine on gastric ulcers in male rats: an experimental study

Article

作者: Shaki, Fatemeh ; Rezaei, Nastaran ; Seyedabadi, Mohammad ; Khanjani, Mohammad Hossein ; Motamednia, Vida ; Amirbeik, Milad ; Shokati Sayyad, Mohammad ; Talebpour Amiri, Fereshteh

Gastric ulcers are a common gastrointestinal disorder associated with significant morbidity and mortality. It can also increase the risk of gastric cancer. This study aimed to investigate the effect of benfotiamine on experimentally-induced gastric ulcers in male rats. In this study, 30 Wistar male rats were divided randomly into six groups: control (normal), indomethacin, omeprazole, and treatment groups, including 50, 100, and 200 mg/kg of benfotiamine. Gastric ulcer was induced by indomethacin gavage. Omeprazole and different therapeutic doses of benfotiamine were administered for three days. Twenty-four hours after the last treatment, the rats were euthanized, and samples were collected.The results demonstrated that 100 and 200 mg/kg of benfotiamine treatment significantly improved indomethacin-induced gastric tissue damage. Moreover, benfotiamine at 100 and 200 mg/kg effectively attenuated the levels of pro-inflammatory cytokines IL-6 and TNF-α and oxidative stress markers MDA and ROS while increasing the antioxidant GSH. These findings suggest that benfotiamine's gastroprotective effects are mediated through its antioxidant and anti-inflammatory properties, which help mitigate the tissue damage and inflammatory response associated with indomethacin-induced gastric ulcers.However, further research is needed to elucidate the precise molecular mechanisms underlying these beneficial effects and to evaluate the potential therapeutic application of benfotiamine in clinical settings.

项与苯磷硫胺素相关的新闻（医药）

2025-01-27

·PRNewswire

Blue Toad Botanicals Launches You've Got Some NERVE™ Stack Featuring Vanizem™ Aframomum melegueta Extract

Synergistic Formulation Designed to Support Healthy Nerve Function MORRISTOWN, N.J., Jan. 27, 2025 /PRNewswire/ -- PLT Health Solutions, Inc. announced that Blue Toad Botanicals™ (Boise, ID USA), a premium lifestyle brand that delivers targeted therapeutic functional mushrooms and botanical stacks has launched a new consumer health product called You've Got Some NERVE™ Functional Mushroom Capsules. The product features PLT Health Solutions' Vanizem™ Aframomum melegueta, which has been clinically demonstrated to improve mood and sleep. The complex formulation for You've Got Some NERVE™ consists of functional mushrooms and a broad range of cutting-edge botanicals and vitamins. This one-of-a-kind stack includes a potent blend of Neuro AEA™ (Anandamide & Myristicin), Feverfew, Passion Flower, Skullcap, Neuro AGARIC™ (Muscimol), Methylated B-Complex, Benfotiamine, Proprietary Terpene Stack and Acetyl-L-Carnitine. Continue Reading You've Got Some NERVE™ consists of functional mushrooms and a broad range of cutting-edge botanicals and vitamins. This one-of-a-kind stack includes a potent blend of NeuroAEA™ (Anandamide & Myristicin), Feverfew, Passion Flower, Skullcap, NeuroAGARIC™ (Muscimol), Methylated B-Complex, Benfotiamine, Proprietary Terpene Stack and Acetyl-L-Carnitine. Vanizem is a proprietary selection and extraction of the West African flowering plant Aframomum melegueta (Grains of Paradise) with standardized bioactives, including 10% vanilloids where 1.5% of them are 6-Paradol that target the endocannabinoid system. Launched in January 2025, You've Got Some NERVE™ is available direct-to-consumer via the Internet and at . According to Co-founder & CEO/Chief Innovation Officer Paul Frantellizzi of Blue Toad, the development and launch of this new product is in line with the company's mission to offer premium quality ingredients with quality science that consumers will actually feel when they consume them. "Living with nerve issues can be challenging and can take a significant toll on people's quality of life. It can affect mood, sleep and impact overall quality of life. Our goal is to empower people to take a more active role in their health and lifestyle and discover effective strategies for supporting neurologic health. Informing the development of this product was my own history of struggling with these issues, he said. The addition of a branded, clinically studied ingredient like Vanizem to this formulation helps us build trust with our customers and offers new, disruptive benefits to our product. We were extremely excited about the standardized content of 10% vanilloids," he added. Vanizem: A unique botanical solution Vanizem is a proprietary selection and extraction of the West African flowering plant Aframomum melegueta (Grains of Paradise) with standardized bioactives, including 10% vanilloids where 1.5% of them are 6-Paradol that target the endocannabinoid system. In a recently completed clinical study, Vanizem was shown to provide improvements in self-reported tension scores (POMS) and significant improvements in sleep quality score (LSEQ) along with improvements in mood, vigor, ease of falling asleep and easier morning awakening.* Studies showed that a low dose showed significant results in improving mental wellbeing, reducing stress and anxiety levels, supporting sleep and contributing to overall relaxation.within just three days.* The ingredient was developed by PLT innovation partner Nektium Pharma (Las Palmas, Spain). PLT Health Solutions is the exclusive sales and marketing partner for Vanizem in North America. According to Steve Fink, Vice President of Marketing for PLT Health Solutions, Blue Toad is an exciting and innovative company in the health and wellness space. "The team at Blue Toad 'get' what self-care through the use of botanicals is all about. They were one of the first companies that recognized the potential for Vanizem. We are excited at the launch of this new product and look forward to more people being introduced to the benefits of Vanizem," he said. For more information on Blue Toad Botanicals, visit bluetoadbotanicals.com For more information on Vanizem, visit plthealth.com/vanizem *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Blue Toad Botanicals™ products are not intended to diagnose, treat, cure, or prevent any medical disorder or disease. About Blue Toad Founded in early 2021 by Pamela Peters & Paul Frantellizzi, Blue Toad™ is a Boise-based, award-winning, and extremely disruptive team of industry professionals developing premium functional-mushroom and targeted therapeutic microdose stacks that solve consumer problems. We understand that gut-health is key to homeostasis & building upon that premise, we use patented, clinically validated ingredients & botanical stacks giving consumers need-state support for Mood, Pain, Sleep, Anxiety, Hormones, Immunity, etc. Blue Toad™ is currently well positioned to be the next big brand in the functional mushroom & wellness industry. About PLT Health Solutions Headquartered in Morristown, NJ, USA, PLT Health Solutions is a trusted discoverer, developer, and marketer of high-quality, scientifically supported ingredients that enhance health and functionality. As a leading ingredients innovator, PLT's global network of strategic partnerships provides unique access to impactful solutions. PLT Health Solutions is a purpose-driven company passionate about helping people live healthier, happier lives. By delivering an unsurpassed mix of expertise, resources, and service, PLT is committed to helping both its strategic partners and valued customers grow. SOURCE PLT Health Solutions WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-01-19

·国际糖尿病idiabetes

年终盘点 | 聚焦糖尿病管理一大难题——DPN临床治疗进展

点击“蓝字”关注我们年终盘点微专辑扫描二维码可查看更多内容黄鑫茹博士刘芳教授上海交通大学医学院附属第一人民医院糖尿病神经病变（DPN）一直以来都是临床治疗难点，目前采取的干预措施主要包括针对发病机制和对症止痛两方面。本刊特邀上海交通大学医学院附属第一人民医院刘芳教授盘点当前DPN临床治疗进展，以期为广大临床医生了解领域最新动向提供参考。一无痛性DPN 此类患者主要症状为四肢麻木、手套袜套样感觉迟钝，甚至感觉丧失，由于可能无法感知轻微的伤害或温度变化，故发生足病的风险增加。治疗方面，目前除了对血糖、血脂和血压等进行代谢控制外，一项小样本临床研究显示生活方式干预（低热量饮食减重、足踝锻炼性运动）也能够延缓糖尿病下肢神经病变的进展[1]；临床上主要还是依靠药物进行针对发病机制的对因治疗。当前临床中广泛应用的针对DPN发病机制治疗的药物包括神经修复药物甲钴胺、强抗氧化剂α-硫辛酸、醛糖还原酶抑制剂依帕司他、改善微循环的前列腺素制剂等血管扩张剂，以及改善神经细胞能量代谢的乙酰左卡尼汀等。除了活性维生素B12（甲钴胺）外，其他B族维生素衍生物也有作用。一项Ⅲ期随机对照试验（RCT）观察了维生素B1衍生物苯磷硫胺（300 mg/次，2次/d）连续口服1年对DPN患者的治疗作用，结果表明苯磷硫胺可以改善DPN患者的神经症状评分[2]。胰高糖素样肽-1（GLP-1）具有营养神经的作用[3]，且GLP-1受体在背根神经节神经元中也有表达。一项新研究纳入22例2型糖尿病（T2DM）患者，使用GLP-1受体激动剂（GLP-1RA）利拉鲁肽或司美格鲁肽治疗并随访3个月[4]。结果表明，81.8%的患者在治疗前外周神经束体积已出现病理性增大，随访结束后93%的患者神经束体积有所减小，同时神经病变的严重程度降低，感觉神经传导波幅改善。二肽基肽酶-4抑制剂（DPP-4i）通过抑制DPP-4酶活性，延长GLP-1半衰期而发挥降糖作用。有研究发现，DPP-4i可促进外周神经系统的神经轴突伸长，发挥营养神经的作用[5]。因此，GLP-1RA和DPP-4i均为有前景的DPN治疗药物，值得进一步研究证实。同样地，另一类降糖药物钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）在治疗DPN方面也显示出一定潜力。研究表明，SGLT2i如恩格列净治疗3个月后可显著改善DPN患者的神经电生理参数，包括改善腓总神经和胫后神经的反射延迟时间、波幅和传导速度[6]。需要指出的是，SGLT2i的主要作用仍是控制血糖，因此DPN患者在使用这类药物时，还应配合血糖监测、生活方式干预等标准治疗方法。其他新型疗法如C肽皮下注射、肌醇磷酸寡糖、神经生长因子、维生素D等也逐渐被发现和研究。值得一提的是，维生素D缺乏与T2DM人群DPN患病和足溃疡发病显著相关。RCT研究表明，大剂量（800 IU/d，40 000 IU/周）而非小剂量（400 IU/d）补充维生素D，可改善糖尿病神经症状评分（NSS），延缓神经损害进展[7]。二痛性DPN 痛性DPN，又称糖尿病痛性周围神经病变（DPNP），患者主要表现为刺痛、烧灼痛、刀割痛、电击样痛、虫咬痛等各种形式的神经病理性疼痛，严重者可影响日常活动，导致失眠、焦虑和抑郁等社会心理障碍，明显降低患者的生活质量。目前，针对糖尿病痛性神经病变主要是对症止痛治疗，包括药物和非药物治疗两方面。 0 1 止痛药物疗法对症治疗的一线药物包括钙离子通道调节剂普瑞巴林、5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRI）度洛西汀、三环类抗抑郁药（TCA）阿米替林；二线药物如阿片类镇痛药物，由于具有成瘾性，应尽可能避免使用。局部应用药物贴膏也有一定的临床证据，主要包括辣椒素膏/贴剂和利多卡因贴剂，局部外用的8%辣椒素贴片已于2020年7月获得美国食品药品监督管理局（FDA）正式批准，用于成人PDPN患者的治疗。第三代钙离子通道调节剂美洛加巴林、克利加巴林备受关注。于亚洲进行的两项多中心、双盲、安慰剂对照的Ⅲ期临床研究表明，美洛加巴林10 mg bid组和15 mg bid组患者的每日疼痛评分较基线显著改善[8,9]。2024年，一项由北京大学郭晓蕙教授牵头的多中心、双盲、安慰剂和普瑞巴林对照RCT发现，自治疗第1周起，苯磺酸克利加巴林（HSK16149胶囊）40/80 mg/d显著改善患者疼痛，给药无需滴定，快速起效，且第1~13周均能显著缓解疼痛，而普瑞巴林在第6~13周发挥疗效；此外，克利加巴林治疗的安全性良好，长期用药依从性高，不良反应以轻至中度头晕和嗜睡最为常见[10]。同年5月，克利加巴林成为中国大陆首个获批痛性DPN适应证的药物。此外，新型药物如肝细胞生长因子（HGF）、血管紧张素Ⅱ受体2拮抗剂以及新型的强效Nav1.7阻滞剂等正在研究或已进入临床试验阶段。一项用质粒制备的HGF治疗DPNP的3期临床研究结果显示，在0、14、90、104天时注射4次HGF制剂VM202，在前9个月的间断治疗期间，HGF并未显著改善神经疼痛，而在不用药的9~12个月延长观察期内，该药明显缓解疼痛，且作用持续到最后一次用药的8个月后，尤其在未服用过加巴喷丁和普瑞巴林的患者中疗效明显，且无明显副作用发生[11]。当然，HGF的安全性和长期缓解疼痛的效果仍需进行更多临床研究加以证实。 0 2 非药物疗法非药物治疗如电刺激治疗、针灸疗法、神经阻滞/阻断、认知行为疗法、运动和理疗已被系统地研究。一项长达8~10年的随访研究表明，脊髓电刺激是减轻痛性DPN患者疼痛强度的有效方法[12]。小型单盲RCT发现，神经内电刺激治疗可改善痛性DPN患者的总体疼痛感觉、复合静态平衡评分和保护性感觉[13]。然而，包含23项RCT的综述指出，经皮神经电刺激和调频电磁神经刺激无明显止痛效果[14]。迄今关于针灸和认知行为疗法改善DPNP的证据仍不足。结语 DPN病理生理机制尚未完全阐明，仍缺乏有效改善疾病的疗法，目前治疗主要包括良好的代谢管理，并进行生活方式干预，以期延缓疾病进展。对于病情明显或加重的DPN患者，则应尽早积极单用或联合应用针对发病机制的药物，并进行相应的足部护理和定期检查。针对当前存在的巨大未被满足的DPN治疗需求，亟待开展相关研究来攻克这一临床难题。参考文献（上下滑动可查看） 1. Ghavami H, et al. Agri. 2018; 30(4): 165-170. 2. Bönhof GJ, et al. BMJ Open. 2022; 12(2): e057142. 3. Miyashita A, et al. Int J Mol Sci. 2023; 24(6): 5977. 4. Dhanapalaratnam R, et al. Diabetologia. 2024; 67(3): 561-566. 5. Goldney J, et al. Diabetologia. 2023; 66(10): 1832-1845. 6. El-Haggar SM, et al. Med Clin (Barc). 2024; 163(2): 53-61. 7. Putz Z, et al. Clin Ther. 2022; 44(5): 813-823. 8. Baba M, et al. J Diabetes Investig. 2019; 10(5): 1299-1306. 9. Kato J, et al. Pain. 2019; 160(5): 1175-1185. 10. Guo X, et al. JAMA Netw Open. 2024; 7(8): e2425614. 11. Kessler JA, et al. Clin Transl Sci. 2021; 14(3): 1176-1184. 12. Zuidema X, et al. Neuromodulation. 2023; 26(5): 1074-1080. 13. Sahba K, et al. J Int Med Res. 2022; 50(8): 3000605221109390. 14. Amato Nesbit S, et al. Curr Med Res Opin. 2019; 35(1):15-25. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果临床2期基因疗法临床3期

2024-09-23

·PRNewswire

A PILL FOR ALZHEIMER'S DISEASE? CLINICAL TRIALS ON A NEW APPROACH TO TREATING ALZHEIMER'S STARTS AT 50 MEDICAL CENTERS ACROSS THE COUNTRY

NIH-funded trial will evaluate the effects of a synthetic version of vitamin B1 on cognitive function that was developed by Burke Institute for people with early Alzheimer's disease For more information about the trial and to find a study site, visit benfoteam.org WHITE PLAINS, N.Y., Sept. 23, 2024 /PRNewswire/ -- A completely different approach to stopping the progression of Alzheimer's disease pioneered by a research institute based in Westchester County, NY is now being tested nationwide. The Burke Neurological Institute (BNI), an affiliation of Weill Cornell Medicine, in partnership with the Alzheimer's Disease Cooperative Study (ADCS) at University of California San Diego and Columbia University Irving Medical Center, have launched a national clinical trial to investigate the therapeutic potential of a BNI and Weill Cornell Medicine-developed form of benfotiamine, a synthetic version of vitamin B1 (thiamine), as a treatment for mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The BenfoTeam trial (The Phase 2A-2B study) taking place at 50 sites across the U.S. will evaluate the effects of benfotiamine on cognitive function and whether high doses benefit people 50-89 with mild AD and MCI. The trial is funded by the National Institute on Aging (NIA), a part of the National Institutes of Health (NIH). Benfotiamine is a synthetic drug which can increase blood thiamine up to 100 times the normal level. These levels of blood thiamine cannot be achieved by taking thiamine alone. The brain tissue in people with AD shows a thiamine deficiency, even with a sufficient supply of thiamine in a person's blood. The trial is investigating whether the delivery of thiamine via drug will increase the amount of thiamine getting to the brain and slow cognitive decline in people with early AD. Currently, 5.8 million Americans are living with AD with this number projected to rise to nearly 14 million people by 2050. "The approach of using benfotiamine in patients with mild Alzheimer's is very promising," said Rajiv Ratan, M.D., Ph.D., Executive Director at Burke Neurological Institute. "This clinical trial builds on years of hard work to address a disease that affects millions of patients " Howard Feldman, Director of the ADCS at UC San Diego said, "The launch of the BenfoTeam clinical trial represents a fresh approach with a potential treatment that is readily accessible, scientifically compelling, and cost-effective – that's a trifecta for a potential AD therapy in a Phase 2 trial – and benfotiamine has a strong safety profile." Gary E. Gibson, Ph.D., Professor of Neurosciences at BNI, has spent decades conducting studies to better understand Alzheimer's disease and how to develop new therapies to treat the disease. The BenfoTeam study builds on Gibson's scientific research conducted at Burke Neurological Institute – the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord. Gibson said many existing treatments or drugs in development only treat the symptoms of Alzheimer's disease such as amyloid plaques, but do not address the root cause of the disease. Benfotiamine has been shown to improve memory and diminish plaques, tangles, inflammation, and oxidative stress in animal models. In addition, unlike many of the other recently approved treatments for Alzheimer's disease, benfotiamine can be taken by mouth and does not require infusions. "In people with Alzheimer's disease, reductions in brain glucose utilization track closely with cognitive decline and we already know that thiamine deficiencies can cause dementia," said Gibson, who is also a Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine. "We think people with mild cognitive impairment and Alzheimer's disease may not be getting enough thiamine delivered to the brain." Jose Luchsinger, M.D., MPH, Vice-Chair for Clinical and Epidemiologic Research at Columbia University and a BenfoTeam trial co-Principal Investigator said, "While Alzheimer's disease impacts all aging populations, it is not clear that recently approved Alzheimer's therapies benefit underrepresented racial and ethnic groups. The BenfoTeam trial is designed for all patient populations.'' Participation in the trial for each patient will last 18 months (plus screening) and enrollment is planned for 406 participants. For more information about the trial and to find a study site, visit benfoteam.org or call 877-807-1290 (toll free). This research will be supported by the NIH's National Institute on Aging (R01AG076634). This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH's National Institute on Aging. The ClinicalTrials.gov ID number for this study is: NCT06223360. About the BenfoTeam Partnership The BenfoTeam clinical research trial is funded by a grant from the National Institute on Aging (NIA) (R01AG076634). The clinical research trial is coordinated by the Alzheimer's Disease Cooperative Study (ADCS) at University of California San Diego School of Medicine and is led by principal investigators from the Burke Neurological Institute and Weill Cornell Medicine, Columbia University Irving Medical Center, and UC San Diego. SOURCE Burke Neurological Institute WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期

100 项与苯磷硫胺素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01255	苯磷硫胺素	A11DA03	DB11748

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
硫胺素缺乏症	日本	Daiichi Sankyo Co., Ltd.	2022-08-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床2期	美国	National Institute on Aging	2015-02-15
胶质母细胞瘤	临床前	美国	Noorda College of Osteopathic Medicine LLC	2025-04-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02292238 (Benfotiamine, CTgov)	临床2期	阿尔茨海默症	71	Benfotiamine (Benfotiamine)	願齋築鏇獵壓簾獵齋齋(鏇鑰範鹽構艱壓積蓋艱) = 餘廠糧築鹹製網鏇艱膚簾艱鑰窪範獵鹹簾壓願 (鹽繭醖構鏇簾積廠窪獵, 5.63) 更多	-	2022-06-28
				Benfotiamine (Placebo)	願齋築鏇獵壓簾獵齋齋(鏇鑰範鹽構艱壓積蓋艱) = 製鏇衊繭願願顧襯齋鬱簾艱鑰窪範獵鹹簾壓願 (鹽繭醖構鏇簾積廠窪獵, 5.52) 更多
EASD2020	N/A	糖尿病性神经病变	-	Benfotiamine 300 mg/day	衊糧蓋衊顧顧憲壓遞蓋(簾網夢淵壓蓋醖鏇衊齋) = 壓衊蓋選選遞獵製艱顧衊鬱觸衊選衊壓夢鹽憲 (鹹遞構餘鹹憲壓餘窪餘 ) 更多	-	2020-09-24
				Alpha-lipoic acid 600 mg/day	衊糧蓋衊顧顧憲壓遞蓋(簾網夢淵壓蓋醖鏇衊齋) = 繭蓋鏇窪範遞憲構範餘衊鬱觸衊選衊壓夢鹽憲 (鹹遞構餘鹹憲壓餘窪餘 ) 更多
NCT00680121 (B1AS, CTgov)	临床4期	酗酒	120	Placebo (Control Group)	網鬱選簾遞糧壓願遞夢(鬱構艱醖鏇蓋選鏇壓鹹) = 鹽顧獵窪築繭蓋蓋窪夢齋鹽觸範願鹹獵艱積鏇 (遞網醖艱鬱獵鹽憲艱窪, 3.6) 更多	-	2014-09-25
				Benfotiamine (Benfotiamine)	網鬱選簾遞糧壓願遞夢(鬱構艱醖鏇蓋選鏇壓鹹) = 簾顧蓋鏇糧艱醖鹽顧鹹齋鹽觸範願鹹獵艱積鏇 (遞網醖艱鬱獵鹽憲艱窪, 4.6) 更多
ASN2010	N/A	帕金森病	-	Benfotiamine	鏇糧淵鹹壓窪獵鹹糧餘(遞鹹鏇艱獵艱憲夢鹽範) = 夢糧壓範繭壓顧夢艱網積選繭遞壓顧遞膚積衊 (鹹鹹鹹齋襯願選壓網願 )	-	2010-11-16
				Placebo	鏇糧淵鹹壓窪獵鹹糧餘(遞鹹鏇艱獵艱憲夢鹽範) = 醖鏇築築餘獵繭鏇蓋窪積選繭遞壓顧遞膚積衊 (鹹鹹鹹齋襯願選壓網願 )